Biotech RadarJobs updated

COMPANY

SK Life Science

HQ: Paramus, NJ (US office) source · sklifescienceinc.com ↗

Status: Acquired, now part of SK Biopharmaceuticals · How status works

Clinical Phase 3

15 open jobs · last seen Oct 23, 2026 · 42 sources

Keywords: cancer Partial Epilepsy Seizures Lennox Gastaut Syndrome Epilepsy Complex Partial Seizures Complex Partial Epilepsy Partial Epilepsies Painful Diabetic Neuropathy Epilepsy, Partial, Motor Simple Partial Epilepsy Focal Motor Epilepsy Focal Epilepsy Seizure Disorder Selected Advanced Solid Tumors Colorectal Cancer Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer Gastric Cancer Esophageal Cancer Head and Neck Squamous Cell Cancer Focal Onset Seizure Primary Generalized Epilepsy Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy Partial Seizure Focal Seizure Hepatic Impairment Postherpetic Neuralgia Neuralgia Herpes Zoster Diabetic Neuralgia Diabetic Polyneuropathy Diabetic Mononeuropathy Schizophrenia Chronic Idiopathic Constipation Chronic Constipation Functional Constipation Movement Disorders Essential Tremor Diabetic Neuropathies Migraine Headaches Refractory Epilepsy

Location: Paramus, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

15Open jobs43Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Marketing Development Manager- NortheastUS | US-PA | US-NJNot statedOct 16, 2026
Contract & Rebate AnalystUSNot statedOct 16, 2026
TMF (Trial Master File) SpecialistUS-NJ-ParamusNot statedOct 16, 2026
Neuroscience Account Manager - Winston SalemUSNot statedOct 16, 2026
Associate Director, CMC Analytical DevelopmentUS-NJ-ParamusNot statedOct 16, 2026

See all 15 jobs

Timeline

  1. Trial start Phase 1: SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors source ↗
  2. Trial start Phase 4: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy source ↗
  3. Trial start Phase 1: A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally source ↗
  4. Trial start Phase 1/Phase 2: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients source ↗
  5. Trial start Phase 3: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults source ↗
  6. Trial start Phase 3: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures source ↗
  7. Trial start Phase 1: Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment source ↗
  8. Trial start Phase 1: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures source ↗
  9. Trial start Phase 3: Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS source ↗
  10. Trial start Phase 1: Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet source ↗
  11. Trial start Phase 1: Bioavailability and Food Effect Study of 3 Types of Carisbamate source ↗
  12. Trial start Phase 1: Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects source ↗
  13. Trial start Phase 3: Cenobamate Open-Label Extension Study for YKP3089C025 source ↗
  14. Trial start Phase 1: Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome source ↗
  15. Trial start Phase 1: Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome source ↗
  16. Trial start Phase 3: Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures source ↗
  17. Trial start Phase 1: A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users source ↗
  18. Trial start Phase 1: Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions source ↗
  19. Trial start Phase 3: Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures source ↗
  20. Trial start Phase 1/Phase 2: A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia source ↗
  21. Trial start Phase 2: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation source ↗
  22. Trial start 2: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures source ↗
  23. Trial start 2: A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation source ↗
  24. Trial start 2: A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy source ↗
  25. Trial start Phase 2: Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures source ↗

Showing 25 of 42 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 43

RecordTitlePhaseStatusStartPrimary completion
NCT07812805SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid TumorsPhase 1RecruitingAug 19, 20262030-07 (estimated)
NCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPhase 3Active, not recruitingJan 10, 20222026-11 (estimated)
NCT06453213Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyPhase 4Active, not recruitingOct 14, 2024May 26, 2027 (estimated)
NCT03678753Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresPhase 3CompletedOct 3, 2018May 26, 2025 (actual)
NCT03961568Cenobamate Open-Label Extension Study for YKP3089C025Phase 3CompletedAug 13, 2019Jun 10, 2026 (actual)
NCT04557085Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSPhase 3CompletedMar 8, 2021Feb 16, 2024 (actual)
NCT04903314Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresPhase 1CompletedMay 27, 2021Nov 6, 2025 (actual)
NCT05219617Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsPhase 3RecruitingApr 28, 20222027-02 (estimated)
NCT01866111A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures2CompletedJul 31, 2013Apr 5, 2021 (actual)
NCT05388435Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors PatientsPhase 1/Phase 2TerminatedSep 12, 2022Mar 1, 2024 (actual)
NCT03509285A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug UsersPhase 1CompletedMar 8, 2017Nov 18, 2017 (actual)
NCT05572255A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered OrallyPhase 1CompletedSep 27, 2022Jan 28, 2023 (actual)
NCT03234699Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug InteractionsPhase 1CompletedFeb 22, 2017Jul 3, 2017 (actual)
NCT04690751Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and TabletPhase 1CompletedDec 21, 2020May 17, 2021 (actual)
NCT02535091Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresPhase 3CompletedAug 3, 2016Mar 31, 2021 (actual)
NCT04062981Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut SyndromePhase 1CompletedMay 3, 2019Dec 14, 2022 (actual)
NCT04791553Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic ImpairmentPhase 1CompletedJun 17, 2021Nov 15, 2022 (actual)
NCT04505397Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy SubjectsPhase 1CompletedFeb 13, 2020Oct 27, 2022 (actual)
NCT03731715Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut SyndromePhase 1CompletedFeb 7, 2019May 23, 2022 (actual)
NCT01397968Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresPhase 2CompletedJul 6, 20112013-06 (actual)
NCT04513860Cenobamate Expanded Access Program (EAP)Not listedApproved for marketingNot listedNot listed
NCT04520360Bioavailability and Food Effect Study of 3 Types of CarisbamatePhase 1CompletedAug 27, 2020Oct 6, 2021 (actual)
NCT00492323An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).Phase 2Completed2007-032008-06 (actual)
NCT00501202Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).Phase 2Completed2007-032008-05 (actual)
NCT02205099A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable SchizophreniaPhase 1/Phase 2Completed2014-072015-06 (actual)
NCT01521598A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy2Completed2012-012013-06 (actual)
NCT01989234A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic ConstipationPhase 2Completed2013-102014-09 (actual)
NCT01523184A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation2Completed2012-032013-11 (actual)
NCT00616148Efficacy of YKP3089 in Patients With Photosensitive EpilepsyPhase 2Completed2007-082009-01 (actual)
NCT00991757An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.Phase 3Completed2007-022010-10 (actual)
NCT00744731An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresPhase 3Completed2009-012010-08 (actual)
NCT00563459Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.Phase 3Terminated2007-112010-04 (actual)
NCT00210522An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyPhase 2Completed2005-052010-06 (actual)
NCT00524056A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential TremorPhase 2Completed2007-082008-03 (actual)
NCT00870454An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in DiabeticsPhase 2Completed2009-052010-12 (actual)
NCT00740623A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.Phase 3Completed2009-012009-10 (actual)
NCT00210652An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyPhase 2Completed2004-072010-03 (actual)
NCT00697762Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresPhase 3Terminated2007-102008-05 (actual)
NCT00697918Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresPhase 3Completed2008-032009-04 (actual)
NCT00109083A Study of the Efficacy of RWJ-333369 in the Prevention of MigrainePhase 2Completed2002-032006-02 (actual)
NCT00228969Safety and Efficacy of 333369 in the Treatment of Partial EpilepsyPhase 2Completed2005-022006-05 (actual)
NCT00425282A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.Phase 3Completed2006-112007-10 (actual)
NCT00433667A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.Phase 3Completed2006-112007-10 (actual)

Open jobs 15

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Marketing Development Manager- NortheastUS | US-PA | US-NJNot statedOct 16, 2026Not stated
Contract & Rebate AnalystUSNot statedOct 16, 2026Entry
TMF (Trial Master File) SpecialistUS-NJ-ParamusNot statedOct 16, 2026Mid
Neuroscience Account Manager - Winston SalemUSNot statedOct 16, 2026Mid
Associate Director, CMC Analytical DevelopmentUS-NJ-ParamusNot statedOct 16, 2026Senior
Marketing Development Manager- New EnglandUS-MA | US | US-RI | US-NYNot statedOct 16, 2026Not stated
Associate Director/Director, Project ManagementUSNot statedOct 16, 2026Senior
Senior Director, Commercial Production Management (CPM) StrategyUS-NJ-ParamusNot statedOct 16, 2026Senior
Manager/Sr. Manager, Analytical Method Development - RadiopharmaceuticalsUS-NJ-ParamusNot statedOct 16, 2026Senior
Senior AI Solutions Engineer, Business TransformationUS-NJ-ParamusNot statedOct 16, 2026Senior
Associate Director, Clinical PharmacologyUS-NJ-ParamusNot statedOct 16, 2026Senior
Neuroscience Account Manager - New Brunswick, NJUSNot statedOct 16, 2026Mid
Director, GCP Quality Inspection ManagementUS-NJ-ParamusNot statedOct 16, 2026Senior
AI Engineer, Business OperationsUS-NJ-ParamusNot statedOct 16, 2026Mid
AI Scientist, Agentic AI (R&D)US-NJ-ParamusNot statedOct 16, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at SK Life Science on LinkedIn

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback